Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer | Zendy

Karim Fizazi | Zendy; NamPhuong Tran | Zendy; Luis Fein | Zendy; Nobuaki Matsubara | Zendy; A. Rodrı́guez-Antolı́n | Zendy; B. Yа. Alekseev | Zendy; Mustafa Özgüroğlu | Zendy; Dingwei Ye | Zendy; Susan Feyerabend | Zendy; Andrew Protheroe | Zendy; Peter De Porre | Zendy; Thian Kheoh | Zendy; Youn C. Park | Zendy; Mary B. Todd | Zendy; Kim N. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Author(s) -

Karim Fizazi,

NamPhuong Tran,

Luis Fein,

Nobuaki Matsubara,

A. Rodrı́guez-Antolı́n,

B. Yа. Alekseev,

Mustafa Özgüroğlu,

Dingwei Ye,

Susan Feyerabend,

Andrew Protheroe,

Peter De Porre,

Thian Kheoh,

Youn C. Park,

Mary B. Todd,

Kim N.

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1704174

Subject(s) - medicine , abiraterone acetate , prostate cancer , prednisone , hazard ratio , placebo , androgen deprivation therapy , interim analysis , urology , clinical endpoint , oncology , surgery , randomized controlled trial , cancer , confidence interval , pathology , alternative medicine

Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research